Trial · NCT00825266
Insulin Resistance in Pulmonary Arterial Hypertension
NCT00825266, Phase 2, Terminated, Stanford University; results first posted 2017-03-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Insulin Resistance in Pulmonary Arterial Hypertension. Trials, record NCT00825266. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00825266
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Insulin Resistance in Pulmonary Arterial Hypertension
- NCT number
- NCT00825266
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Hypertension, Pulmonary
- Interventions
- bosentan, Pioglitazone
- First posted
- 2009-01-21
- Last updated
- 2017-03-31
- Results first posted
- 2017-03-31
- Limitations and caveats
- Study terminated due to poor enrollment
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio | baseline and 16 weeks | insulin resistance measured -triglyceride: HDL cholesterol ratio measures at 16 weeks compared with baseline. |
| Secondary | 6 Minute Walk Test | Baseline and 16 weeks | 6 minute walk test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.It assess the disease severity of the subject at 16 week compared to the baseline. |
| Secondary | NYHA (New York Heart Association Classification) Changes | Baseline and 16 weeks | New York Heart Classification(NYHA) changes measured at 16 weeks compared with baseline. NYHA Classification: NYHA class I:no symptoms and no limitation in ordinary physical activity NYHA class II:Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity NYHA class III:Marked limitation in activity due to symptoms, even during less-than-ordinary activity, NYHA class IV:Severe limitations. Experiences symptoms even while at rest. {Higher NYHA class represent worse symptoms} |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio | baseline and 16 weeks | ratio | NUMBER | |
| SECONDARY | 6 Minute Walk Test | Baseline and 16 weeks | meters | NUMBER | |
| SECONDARY | NYHA (New York Heart Association Classification) Changes | Baseline and 16 weeks | NYHA class | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio | Bosentan | -0.22 | ratio | ||
| Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio | Pioglitazone | -1.96 | ratio | ||
| 6 Minute Walk Test | Bosentan | -71 | meters | ||
| 6 Minute Walk Test | Pioglitazone | -23 | meters | ||
| NYHA (New York Heart Association Classification) Changes | Bosentan | 0 | NYHA class | ||
| NYHA (New York Heart Association Classification) Changes | Pioglitazone | 0 | NYHA class |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bosentan | 1 | |
| Overall Study | STARTED | Pioglitazone | 1 | |
| Overall Study | COMPLETED | Bosentan | 1 | |
| Overall Study | COMPLETED | Pioglitazone | 1 | |
| Overall Study | NOT COMPLETED | Bosentan | 0 | |
| Overall Study | NOT COMPLETED | Pioglitazone | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bosentan | ||
| Total, all-cause mortality | Pioglitazone | ||
| Total, other adverse events | Bosentan | 0 | 1 |
| Total, other adverse events | Pioglitazone | 0 | 1 |
| Total, serious adverse events | Bosentan | 0 | 1 |
| Total, serious adverse events | Pioglitazone | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bosentan vs Pioglitazone: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00825266
GET https://conductscience.org/api/trials/v1/NCT00825266/registered